Filing Details

Accession Number:
0001209191-20-057536
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-09 21:11:12
Reporting Period:
2020-11-05
Accepted Time:
2020-11-09 21:11:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
860730 Hca Healthcare Inc. HCA Services-General Medical & Surgical Hospitals, Nec (8062) 273865930
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1551011 Martin P. Paslick One Park Plaza
Nashville TN 37203
Svp And Cio No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-05 10,000 $47.97 10,000 No 4 M Direct
Common Stock Disposition 2020-11-05 6,052 $137.56 3,948 No 4 F Direct
Common Stock Disposition 2020-11-09 3,948 $148.07 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Appreciation Right Disposition 2020-11-05 6,975 $0.00 6,975 $47.97
Common Stock Stock Appreciation Right Disposition 2020-11-05 3,025 $0.00 3,025 $47.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,525 2024-02-05 No 4 M Direct
0 2024-02-05 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 127,999 Indirect By Spouse
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.94 to $148.17, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015.
  3. The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.